In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Schwarz licenses Ranbaxy's BPH compound

Executive Summary

Schwarz Pharma licensed exclusive US, Japanese, and European development and marketing rights to Ranbaxy Laboratories' RBx-2258 drug candidate for benign prostatic hyperplasia. The compound is in Phase I for the licensed territories, and in Phase II in India, where Ranbaxy retains rights.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies